In practice, it is much closer to a clinical accountability checkpoint: the moment when a company must be able to show that its promotional material is accurate, balanced, consistent with the marketing authorisation, and suitable for the setting in which it will be used.
That distinction matters because the person providing final sign-off is not simply approving wording. Under the ABPI Code, the medical signatory carries a defined regulatory responsibility, and the process depends on more than professional seniority or scientific expertise. A life sciences PhD, a strong publication record, or extensive experience in clinical development does not, on its own, meet the qualification requirement for final medical certification in the UK. The signatory must sit within the boundaries established by the Code, with the appropriate UK registration and a clear separation from the person who developed the material.
For teams navigating the medical signatory review process under the ABPI Code, the central question is therefore not whether a document has been read by someone medically knowledgeable. It is whether the right person has reviewed the final version, under the right authority, against the right evidence and within a workflow that preserves the integrity of the decision.
The final signature is not a rubber stamp at the end of production; it is the point at which clinical responsibility becomes visible.
Defining the medical signatory: qualifications and regulatory boundaries
Under Clause 8.1 of the ABPI Code of Practice, the final medical signatory for relevant promotional material must be a registered medical practitioner or a UK-registered pharmacist. A UK-registered dentist may act in this capacity where the product is intended for dental use only.
This requirement creates a boundary that is sometimes blurred in multinational organisations, particularly where internal job titles are used as shorthand for regulatory authority. A medical director, clinical scientist, safety physician, or global medical affairs lead may be highly qualified to advise on a document. That does not automatically mean that the individual is eligible to provide the final UK sign-off.
The qualification must be understood in relation to the regulatory role, not simply the person’s scientific credibility. Life science PhDs and veterinary qualifications alone do not qualify an individual to act as the final UK medical signatory under the ABPI Code and applicable EFPIA standards. The same applies to a professional whose registration is outside the categories recognised by the Code, even where that person has substantial experience with the product or therapeutic area.
This is not a judgement on the quality of the individual’s expertise. It is a safeguard around the kind of accountability attached to the material. The Code places final certification within a recognised clinical or pharmacy registration framework because the decision may affect how a medicine is understood, prescribed, discussed, or used in the care pathway.
What the signatory is being asked to certify
The signatory’s role is not limited to checking whether claims are scientifically plausible. The review must take account of the complete material and its intended use. Depending on the asset, this may include:
- whether claims are accurate, capable of substantiation, and presented in a balanced manner;
- whether the content is consistent with the product’s marketing authorisation;
- whether the presentation could create a misleading impression through emphasis, omission, visual treatment, or context;
- whether required prescribing information is present or provided through an acceptable mechanism;
- whether references, graphs, comparative statements, and clinical outcomes are used in a way that reflects the underlying evidence;
- whether the final version is the version that will actually be issued.
That last point is particularly important. Promotional material must be certified in its final form before issue. The practical meaning is straightforward but frequently tested by workflow pressure: the document that receives approval cannot later be treated as a flexible template for unreviewed amendments.
A change to a headline, footnote, graph label, reference, dosing statement, indication, or digital interaction may alter the regulatory meaning of the piece. Even a seemingly minor amendment can change balance or introduce a new implication. The medical signatory review process must therefore end with a controlled final artefact, not merely a general approval of the concept.
The relationship between Clause 8.1 and other certification roles
The ABPI Code also recognises an appropriately qualified person, or AQP, in defined certification categories under Clause 8.2. The existence of different certification routes is one reason teams should avoid treating every review as interchangeable. The appropriate reviewer depends on the type of material, the regulatory purpose of the certification, and the qualifications required for that category.
The operational question should be framed early: what kind of material is this, and which certification route applies? A company that waits until the final production stage to resolve that question may find that its internal reviewer is not eligible, that the notification process has not been completed, or that the asset must return to an earlier stage of review.
In a mature compliance system, qualification is not checked only when a signatory is first appointed. It is maintained as part of governance. The organisation should know who its nominated signatories are, what registration they hold, which certification responsibilities they may undertake, and where those details are recorded.
The separation of duties: why the developer cannot be the final certifier
One of the clearest ABPI medical certification requirements is the separation between the person who develops or draws up promotional material and the person who certifies it.
The individual certifying the material on behalf of the company must not be the person responsible for developing or drawing up that material. This is more than a formal conflict-of-interest rule. It recognises a familiar human problem in clinical and regulatory work: once we have invested time and professional judgement in a document, it becomes harder to see its weaknesses with the same distance as someone approaching it afresh.
The separation of duties protects the review from becoming an extension of authorship. A medical signatory should be able to challenge the selected endpoint, the strength of a claim, the placement of a limitation, or the interpretation of a comparative result without also defending the decisions that produced the draft.
What independent review looks like in practice
Independence does not mean the signatory works in isolation. A strong review usually depends on input from medical, regulatory, legal, pharmacovigilance, commercial, and medical information colleagues, depending on the asset. But the final certifier must retain the ability to make an independent decision about whether the material can be issued.
That decision may involve questions such as:
- Is the primary claim supported by the most relevant evidence, or merely by evidence that is convenient to cite?
- Does the visual hierarchy give greater weight to a favourable finding than to a clinically meaningful limitation?
- Is a surrogate endpoint being presented in a way that could be mistaken for a patient-relevant outcome?
- Does a comparison reflect the study design, population, dose, duration, and statistical limitations?
- Is the wording consistent with the approved indication and relevant prescribing information?
- Would a busy healthcare professional understand the message in the same way as the review team intended?
- Does the material remain balanced when viewed quickly, on a screen, or outside the context of the accompanying presentation?
These questions reach beyond proofreading. They are about the lived experience of the information: what a prescriber sees first, what a patient may hear indirectly, and where an apparently careful statement could become misleading once it enters a real care pathway.
A compliant claim is not only one that can be defended in a meeting; it is one that remains responsible when it reaches a busy clinician and, eventually, a patient.
Avoiding the “everyone reviewed it” illusion
Many organisations have several people involved in a review, yet no clearly defined final decision-maker. A document may carry comments from medical affairs, regulatory, legal, and brand teams, but that does not remove the need for an eligible signatory to certify the final version.
The opposite problem also occurs: the nominated signatory is brought in only after the material has been shaped by commercial priorities, at which point the review becomes an attempt to resolve fundamental issues under an artificial deadline. That approach increases patient burden indirectly by creating delays, repeated revisions, and the temptation to treat important balance requirements as production obstacles.
A better workflow brings the medical signatory into the process early enough to influence the evidence strategy and the intended message, while preserving the formal independence required at certification. Early involvement is not the same as early approval. It is a way of ensuring that the final review is focused on responsible refinement rather than discovering that the central claim cannot be supported.
Navigating the 2024 ABPI Code: prescribing information and QR codes
The 2024 ABPI Code of Practice came into effect on 1 October 2024, with a transition period running from 1 October through 31 December 2024. Among the changes relevant to promotional material review is the update to Clause 12, which permits prescribing information to be provided through QR codes for printed and certain digital promotional materials.
For teams, this is a practical development rather than a simple design preference. A QR code can help manage the amount of prescribing information presented in a constrained format, but it does not remove the responsibility to make that information accessible, accurate, and connected to the material being reviewed.
The presence of a QR code should therefore be treated as part of the regulated asset. It belongs inside the medical signatory validation workflow, not in a separate production lane managed after the clinical and regulatory review has finished.
The QR code is part of the claim environment
A signatory reviewing a printed leavepiece or digital asset should be able to understand how the QR code functions at the time of certification. The review should address the destination content, the relationship between the code and the promotional item, and the likelihood that the intended audience can access the prescribing information in practice.
This brings ordinary user experience into the compliance discussion. A code that leads to a missing page, an outdated document, an inaccessible mobile layout, or content that does not match the approved version creates a problem even if the QR graphic itself appears correctly placed.
The review should consider, among other points:
- whether the QR code resolves to the intended prescribing information;
- whether the linked content is the approved and current version;
- whether the code remains functional in the final printed or digital format;
- whether the surrounding wording makes clear what the user will find after scanning;
- whether the prescribing information can be reached without unnecessary friction;
- whether the digital destination has been controlled against later unreviewed changes.
The signatory does not need to become a web developer, but the medical signatory responsibilities in pharma extend to the way information is actually delivered. A technically present disclosure that cannot be reached or understood does not provide the same protection as information that is available in a meaningful way.
Digital convenience and clinical responsibility
The attraction of QR codes is obvious: they can reduce visual congestion and make a printed or digital asset easier to navigate. Yet reducing clutter on the page should not mean moving important context so far away from the main message that it loses practical visibility.
This is where the principle of meaningful endpoints helps. The endpoint of a compliant communication is not the completion of the design file. It is the point at which the healthcare professional can access and interpret the relevant prescribing information while making sense of the promotional message.
A signatory should be alert to the difference between formal inclusion and functional communication. The Code may permit a particular mechanism for providing prescribing information, but the responsibility for a coherent, balanced care pathway remains with the company and its reviewers.
Operationalising joint promotions and signatory notifications
The ABPI framework also allows companies involved in joint promotion or co-promotion to agree that a single final signatory will certify joint materials on behalf of all participating companies, provided that the MHRA and PMCPA are notified in advance.
This can simplify governance. Without a clear arrangement, a joint asset may move through several parallel approval systems, each with its own signatory, evidence expectations, version controls, and escalation routes. That can create duplicated effort without necessarily improving the quality of the final review.
A single nominated signatory can provide a coherent point of accountability, but only when the participating companies have genuinely aligned their responsibilities. The arrangement should not become a way to obscure who owns the material, who supplies the evidence, who manages subsequent changes, or who responds if a concern is raised after issue.
Notification is part of the governance, not a filing detail
Names and qualifications of nominated signatories must be notified in advance to the MHRA Advertising Standards and Outreach Unit and to the PMCPA using the nominated signatories form. The process is therefore not complete simply because an internal appointment has been made.
This notification creates an external record of the individuals authorised to perform the relevant certification role. It also means that organisations need to manage changes carefully. When a signatory joins, leaves, changes role, or no longer meets the intended responsibility profile, the company should not allow the internal document management system to drift away from the notified position.
The practical governance questions include:
- Who is responsible for maintaining the nominated signatory information?
- How is the individual’s UK registration status confirmed?
- Which types of certification can the person undertake?
- How are temporary absences or handovers managed?
- How are joint-promotion responsibilities documented between companies?
- How does the organisation ensure that only authorised signatories can complete final approval?
- Where is the evidence of notification retained alongside the certification record?
These are not merely administrative questions. They determine whether a company can demonstrate that its sign-off process was valid at the time the material was issued.
The joint-signatory arrangement needs a clear operating model
When one signatory acts for several companies, the review should still receive complete input from each participating organisation. Each company may hold relevant evidence, safety information, local regulatory interpretation, or product-specific knowledge. A single final signature does not make those inputs optional.
The parties should agree how disagreements are escalated, who resolves evidence gaps, and whether any company retains a right to withhold approval for its own legal or regulatory reasons. The ABPI Code provides a route for nominating a single final signatory; it does not remove the need for disciplined collaboration.
This is especially relevant where a global asset has been adapted for the UK market. A central team may develop the core content, while a UK team remains responsible for local compliance with the ABPI Code, the product’s UK marketing authorisation, and the practical requirements around prescribing information. The final reviewer needs enough visibility to distinguish a genuinely localised adaptation from a translation or design change that has altered the clinical meaning.
The final certification protocol: from review comments to controlled issue
The final stage of medical signatory review is where process quality becomes visible. A strong protocol gives the signatory a controlled, final version of the material and a clear evidence trail supporting the claims. It also protects the signatory from being asked to approve an asset that continues to change around them.
The review should be performed on the version intended for issue, including its final layout, references, footnotes, linked content, prescribing information mechanism, and any material-specific functionality. A document that is clinically acceptable in a word-processing file may not remain acceptable once the text is shortened, a qualification is moved to a less prominent position, or a graph is reformatted for a digital channel.
A practical medical signatory validation workflow
A useful workflow can be organised into five connected stages:
1. Define the regulatory category and intended use.
Establish whether the item is promotional or falls within a specific non-promotional certification category, who will receive it, where it will appear, and how it will be used in the care pathway. The same wording may carry different implications depending on whether it appears in a sales aid, an email, a website, a congress material, or a professional education setting.
2. Confirm the signatory route and authority.
Verify that the nominated individual meets the relevant qualification requirement, is appropriately registered in the UK, and has been notified to the MHRA and PMCPA where required. Do not rely on job title alone, and do not substitute a scientific qualification for the registration category specified by the Code.
3. Review the evidence and the clinical message.
Assess the claims against the underlying data, the marketing authorisation, relevant references, and the intended audience. Look for imbalance created by presentation as well as by wording. The question is not only whether each sentence is defensible, but whether the overall impression is responsible.
4. Lock the final asset and connected content.
Confirm that the version presented for sign-off is complete. Include final graphics, references, footnotes, prescribing information, QR-code destinations, translations, and channel-specific adaptations. Any later amendment should trigger an appropriate reassessment rather than being treated as a harmless production edit.
5. Record the decision and control issue.
Retain the approved version, the certification record, the evidence reviewed, the date of approval, the identity and qualification of the signatory, and the relevant version information. Issue only the certified form and maintain controls that prevent an obsolete version from remaining in circulation.
This sequence is deliberately practical. It does not turn the review into a mechanical checklist; it gives the signatory enough context to apply clinical judgement without allowing that judgement to disappear into an undocumented conversation.
The meaning of “final form”
The requirement for certification in final form is one of the most consequential details in the ABPI process. It is easy to interpret finality as a matter of file naming, but the underlying issue is control over what the audience receives.
A final file should not be accompanied by an informal understanding that the design team may still adjust spacing, update a reference, replace an image, alter a button label, or change a digital destination. Those changes may appear minor from a production perspective, yet they can affect the prominence, interpretation, or accessibility of the communication.
For that reason, the final sign-off record should connect the approval to a specific version rather than to a general campaign or concept. If the material is adapted across channels, each adaptation should be assessed according to its actual form and use. A website banner, a printed detail aid, and an email may share a claim while presenting different compliance risks.
Handling amendments after approval
Not every post-approval change has the same regulatory significance, and internal procedures will determine how a company categorises and manages amendments. But the safe operational principle is that no change should be assumed to be outside the scope of the review merely because it does not alter the clinical claim.
Changes that commonly warrant careful consideration include:
- alterations to headline wording or claim emphasis;
- changes to references or the data source supporting a claim;
- modifications to dosing, indication, safety, or prescribing information;
- changes to comparative tables, graphs, axis labels, or statistical footnotes;
- movement or reduction of qualifying text;
- replacement of images that changes the implied patient population or treatment context;
- changes to QR-code destinations or linked digital content;
- localisation into another language or adaptation for another audience.
The medical signatory should not be placed in the position of approving a moving target. Clear version control is therefore part of clinical responsibility, because it preserves the connection between the decision made and the information received.
Where compliance meets lived experience
Regulatory compliance can become abstract when discussed only in terms of clauses, forms, and document states. For patients and clinicians, however, the consequences are experienced through ordinary interactions: a prescribing decision made with incomplete context, a safety limitation that is visually diminished, a treatment expectation shaped by an overconfident claim, or a healthcare professional who cannot easily reach the information needed at the point of care.
This is why the medical signatory review process under the ABPI Code deserves more attention than a final administrative gate. It is one of the places where our industry can test whether the communication reflects the reality of clinical work. Healthcare professionals read under time pressure. Patients may encounter treatment information indirectly, through conversations shaped by promotional material. The care pathway is rarely as orderly as the approval workflow that produced the document.
A responsible signatory review keeps those conditions in view without abandoning regulatory precision. It asks whether the evidence has been translated faithfully, whether the message is balanced in practice, and whether the approved material will still make sense when detached from the meeting in which it was discussed.
The strongest processes also recognise that compliance is not produced by the signatory alone. It depends on the quality of the source data, the discipline of the content team, the independence of the review, the reliability of version control, and the willingness of the organisation to slow down when a meaningful endpoint has not been reached.
A more mature view of the final signature
The ABPI medical signatory role is sometimes reduced to a qualification requirement: appoint an eligible clinician or pharmacist, obtain approval, and release the material. That description misses the human and operational substance of the work.
The signatory must be appropriately qualified under the Code, independent from the development of the material, notified through the required channels, and presented with the final version before issue. The 2024 provisions on QR-code delivery of prescribing information add flexibility, but they also make control of digital destinations and user access part of the review. Joint promotions can use a single final signatory where the required notification and governance are in place, but shared accountability still requires transparent collaboration.
Our industry does not need more signatures for their own sake. It needs sign-off that means something: a considered clinical judgement, made by the right person, on the material that patients and healthcare professionals will actually encounter. When the process is designed around that reality, regulatory compliance stops being a late-stage obstacle and becomes part of standard-of-care excellence.